Tags

Type your tag names separated by a space and hit enter

Comparison of the safety, vaccine virus shedding, and immunogenicity of influenza virus vaccine, trivalent, types A and B, live cold-adapted, administered to human immunodeficiency virus (HIV)-infected and non-HIV-infected adults.
J Infect Dis 2000; 181(2):725-8JI

Abstract

Fifty-seven human immunodeficiency virus (HIV)-infected (CDC class A1-2) and 54 non-HIV-infected adults, not prescreened for influenza susceptibility, were randomized to receive trivalent live attenuated influenza vaccine (LAIV) or placebo intranasally. LAIV was safe and well tolerated with no serious adverse events attributable to vaccine. Reactogenicity rates were similar in LAIV and placebo recipients except that runny nose/nasal congestion was significantly more common in LAIV recipients regardless of HIV status. No prolonged shedding of LAIV was observed in HIV-infected participants. HIV RNA levels were not increased and CD4 counts were not decreased in HIV-infected LAIV recipients compared with placebo recipients after immunization. Shedding of LAIV and increases in antibody titers were infrequent, consistent with prior experience in unscreened adults. The data suggest that inadvertent vaccination with LAIV in relatively asymptomatic HIV-infected adults would not be associated with frequent significant adverse events.

Authors+Show Affiliations

Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, MD 21201, USA. jking@som.umaryland.eduNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Comparative Study
Journal Article
Randomized Controlled Trial
Research Support, U.S. Gov't, P.H.S.

Language

eng

PubMed ID

10669363

Citation

King, J C., et al. "Comparison of the Safety, Vaccine Virus Shedding, and Immunogenicity of Influenza Virus Vaccine, Trivalent, Types a and B, Live Cold-adapted, Administered to Human Immunodeficiency Virus (HIV)-infected and non-HIV-infected Adults." The Journal of Infectious Diseases, vol. 181, no. 2, 2000, pp. 725-8.
King JC, Treanor J, Fast PE, et al. Comparison of the safety, vaccine virus shedding, and immunogenicity of influenza virus vaccine, trivalent, types A and B, live cold-adapted, administered to human immunodeficiency virus (HIV)-infected and non-HIV-infected adults. J Infect Dis. 2000;181(2):725-8.
King, J. C., Treanor, J., Fast, P. E., Wolff, M., Yan, L., Iacuzio, D., ... Belshe, R. B. (2000). Comparison of the safety, vaccine virus shedding, and immunogenicity of influenza virus vaccine, trivalent, types A and B, live cold-adapted, administered to human immunodeficiency virus (HIV)-infected and non-HIV-infected adults. The Journal of Infectious Diseases, 181(2), pp. 725-8.
King JC, et al. Comparison of the Safety, Vaccine Virus Shedding, and Immunogenicity of Influenza Virus Vaccine, Trivalent, Types a and B, Live Cold-adapted, Administered to Human Immunodeficiency Virus (HIV)-infected and non-HIV-infected Adults. J Infect Dis. 2000;181(2):725-8. PubMed PMID: 10669363.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Comparison of the safety, vaccine virus shedding, and immunogenicity of influenza virus vaccine, trivalent, types A and B, live cold-adapted, administered to human immunodeficiency virus (HIV)-infected and non-HIV-infected adults. AU - King,J C,Jr AU - Treanor,J, AU - Fast,P E, AU - Wolff,M, AU - Yan,L, AU - Iacuzio,D, AU - Readmond,B, AU - O'Brien,D, AU - Mallon,K, AU - Highsmith,W E, AU - Lambert,J S, AU - Belshe,R B, PY - 2000/2/11/pubmed PY - 2000/4/15/medline PY - 2000/2/11/entrez SP - 725 EP - 8 JF - The Journal of infectious diseases JO - J. Infect. Dis. VL - 181 IS - 2 N2 - Fifty-seven human immunodeficiency virus (HIV)-infected (CDC class A1-2) and 54 non-HIV-infected adults, not prescreened for influenza susceptibility, were randomized to receive trivalent live attenuated influenza vaccine (LAIV) or placebo intranasally. LAIV was safe and well tolerated with no serious adverse events attributable to vaccine. Reactogenicity rates were similar in LAIV and placebo recipients except that runny nose/nasal congestion was significantly more common in LAIV recipients regardless of HIV status. No prolonged shedding of LAIV was observed in HIV-infected participants. HIV RNA levels were not increased and CD4 counts were not decreased in HIV-infected LAIV recipients compared with placebo recipients after immunization. Shedding of LAIV and increases in antibody titers were infrequent, consistent with prior experience in unscreened adults. The data suggest that inadvertent vaccination with LAIV in relatively asymptomatic HIV-infected adults would not be associated with frequent significant adverse events. SN - 0022-1899 UR - https://www.unboundmedicine.com/medline/citation/10669363/Comparison_of_the_safety_vaccine_virus_shedding_and_immunogenicity_of_influenza_virus_vaccine_trivalent_types_A_and_B_live_cold_adapted_administered_to_human_immunodeficiency_virus__HIV__infected_and_non_HIV_infected_adults_ L2 - https://academic.oup.com/jid/article-lookup/doi/10.1086/315246 DB - PRIME DP - Unbound Medicine ER -